

**KENTUCKY BOARD OF PHARMACY
State Office Building Annex, Suite 300
125 Holmes Street
Frankfort KY 40601**

Special Meeting Notice and Agenda

Hazardous Compounding Committee

May 14, 2018
9:00 a.m.

- I. Call to Order

- II. Minutes – April 9, 2018

- III. Sections 5 and 15

- IV. Next meeting – June 11, 2018, Wholesaler Distributors, Sections 6, 7 and 10

- V. Adjournment

Kentucky Board of Pharmacy
Hazardous Drug Compounding Committee

125 Holmes Street
Frankfort KY 40601

May 14, 2018

MINUTES

Chair Matt Martin called the meeting to order at 9:03 a.m. Members present: Barb Jolly, Chris Harlow, Trenika Mitchell and Paul Daniels. Members absent: Alyson Roby, John Carver and Jennifer Grove. Staff: Larry Hadley, Katie Busroe, John Romines, Jessica Williams and Darla Sayre. Guests: Jason Lyddane, St Joseph Hospital;; Robin Walters, Pikeville Medical Center; Adam Parrish, Wal-mart; Willis Triplett, Comply 797; Kristen Blankenbecler, Marcum and Wallace Hospital; Eric Marr, UK College of Pharmacy; Mark Glaspar, KPHA and Philip Schwieterman, KSHP.

On motion by Dr. Harlow, seconded by Dr. Jolly, the minutes of the April 9, 2018 meeting were approved.

Cheryl Lalonde joined the meeting at 9:30 a.m. Amanda Harding joined the meeting at 10:17 a.m.

Section 5: Dr. Jolly questioned if compliance of USP 800 would be too difficult for pharmacies doing only non-sterile compounding. If low volume pharmacies decide not to perform any compounding would this affect patient access? After much discussion, Dr. Mitchell determined that the issues of negative pressure and low volume generators were areas of concern to the committee. Mr. Daniels moved to table the issue of negative pressure until all sections have been reviewed and additional information is provided by KSHP. Dr. Mitchell seconded and the motion passed unanimously. Mr. Daniels moved to take no action on the issue of low volume generators. Dr. Mitchell seconded and the motion passed unanimously.

Section 15: Dr. Martin stated his concern was what agent was to be used for deactivating and disinfecting. Dr. Jolly stated her concern was using the same agent for both non-sterile and sterile compounding creating a greater risk of cross-contamination. Robin Walters stated her concern was the requirement for deactivation/decontamination after each product. This requirement was not practical in a hospital setting for infusion. Dr. Mitchell moved to table this section until all sections have been reviewed. Mr. Daniels seconded, and the motion passed unanimously.

Dr. Mitchell made a motion for the following agenda items for upcoming meetings.

June 11, 2018	Wholesale Distributors, Sections 6, 7 and 10
July 9, 2018	Sections 11, 12, 13, 14, 17 and 18
August 13, 2018	Wrapup

Dr. Harlow seconded, and the motion passed unanimously.

On motion by Mr. Daniels, seconded by Dr. Harlow and passed unanimously, Dr. Martin adjourned at 11:25 a.m.